Connect Biopharma (NASDAQ:CNTB - Get Free Report) was upgraded by Northland Capmk to a "strong-buy" rating in a research report issued on Tuesday,Zacks.com reports. Northland Capmk also issued estimates for Connect Biopharma's Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.23) EPS, Q4 2025 earnings at ($0.27) EPS, FY2025 earnings at ($0.90) EPS, FY2026 earnings at ($0.80) EPS and FY2027 earnings at ($0.75) EPS.
Separately, HC Wainwright began coverage on Connect Biopharma in a report on Thursday, June 12th. They set a "buy" rating and a $7.00 target price on the stock.
Get Our Latest Analysis on Connect Biopharma
Connect Biopharma Stock Down 5.5%
CNTB stock traded down $0.13 during mid-day trading on Tuesday, hitting $2.22. 122,465 shares of the company were exchanged, compared to its average volume of 245,203. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.25 and a quick ratio of 10.25. Connect Biopharma has a twelve month low of $0.51 and a twelve month high of $2.86. The firm has a fifty day simple moving average of $1.13 and a 200 day simple moving average of $0.94.
Connect Biopharma (NASDAQ:CNTB - Get Free Report) last released its earnings results on Thursday, May 15th. The company reported ($0.19) EPS for the quarter, topping analysts' consensus estimates of ($0.26) by $0.07. Equities research analysts expect that Connect Biopharma will post -0.22 EPS for the current year.
About Connect Biopharma
(
Get Free Report)
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets.
Read More
Before you consider Connect Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Connect Biopharma wasn't on the list.
While Connect Biopharma currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access